Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24427865 | 0.86 | KDM4E (0.33) | KDM4EHPGDSMN1; SMN2POLB | |
| SCHEMBL24427243 | 0.84 | KDM4E (0.33) | KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL24427863 | 0.83 | KDM4E (0.31) | KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL17832296 | 0.78 | NOS3 (0.34) | KDM4EHPGDSMN1; SMN2POLB | |
| SCHEMBL24427511 | 0.74 | MAPK14 (0.34) | DYRK1A | |
| SCHEMBL13385779 | 0.73 | ALDH1A1 (0.38) | KDM4ESMN1; SMN2POLB | |
| SCHEMBL24427509 | 0.71 | TRPA1 (0.50) | — | |
| SCHEMBL17832298 | 0.70 | KDM4E (0.42) | KDM4EHPGDSMN1; SMN2PARP1POLB | |
| SCHEMBL24427806 | 0.70 | CYP2A6 (0.39) | — | |
| SCHEMBL24427244 | 0.68 | MPL (0.40) | SMN1; SMN2PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11518766-B2 | Tricyclic compound, preparation method therefor and use thereof | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD. (CN) | 2022-12-06 | — | — | US | disclosed |
| EP-3998263-A1 | TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) | 2022-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11518766-B2 | Tricyclic compound, preparation method therefor and use thereof | TFPI, TFPI2, F11 | KDM4E 3192/4885HPGD 1327/4885SMN1; SMN2 3397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.